Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $18.20.

A number of research firms have weighed in on BWAY. Zacks Research lowered shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. New Street Research restated a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. LADENBURG THALM/SH SH upped their target price on shares of Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, HC Wainwright increased their price target on Brainsway from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 31st.

Brainsway Price Performance

BWAY stock opened at $14.15 on Tuesday. The business’s 50-day moving average price is $15.18 and its 200-day moving average price is $14.72. The stock has a market cap of $568.97 million, a P/E ratio of 32.16 and a beta of 1.25. Brainsway has a twelve month low of $7.14 and a twelve month high of $17.40.

Brainsway (NASDAQ:BWAY) last released its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. The company had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.54 million. On average, equities research analysts expect that Brainsway will post 0.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainsway

A number of hedge funds have recently made changes to their positions in BWAY. NewEdge Advisors LLC grew its position in shares of Brainsway by 61.5% during the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after purchasing an additional 7,549 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Brainsway in the 2nd quarter worth approximately $85,000. UBS Group AG boosted its stake in Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after purchasing an additional 60,877 shares during the period. Two Sigma Investments LP boosted its stake in Brainsway by 25.2% in the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after purchasing an additional 20,706 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Brainsway during the 3rd quarter valued at approximately $107,000. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.